JCV seroconversion and index values may be influenced by treatment with natalizumab. It is therefore important to monitor patients' JCV serology but also to incorporate additional risk factors into the progressive multifocal leukoencephalopathy risk stratification.
No takes yet. Share an insight, caveat, or question.
Schwab et al. (2016) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: